Highly Specific Lyme Disease Test

Technology #32819

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
A tick on human skin
Mollie Jewett, Ph.D.
Micah Halpern, Ph.D.
Managed By
Brion Berman
Sr. Licensing Associate 407.882.0342
Patent Protection

Method, Kits and Materials for Detection of Lyme Disease Borrelia Sp. Infection

PCT Patent Application WO 2015/054319

Using iPCR and a multimeric antigen

Lyme disease has been characterized as the fastest growing zoonotic disease in North America and currently diagnosis is both lengthy and inaccurate. The current method entails a two-step process containing both an enzyme immunoassay as well as an immunoblot. Due to the subjectivity of immunoblot analysis as well as a lack of standardization of antigen source and lysate preparations this process can be extremely imprecise.


UCF researchers discovered a Lyme disease diagnostic that can determine both the stage and type of disease caused by a Borrelia species. This detection method combines the sensitivity of PCR with the specificity and versatility of immunoassay-based protocols. By combining the iPCR approach with a single multimeric antigen, the specificity was further increased. The diagnostic reduces the cost and complexity of current testing and, more importantly, provides a means of reagent standardization, which is lacking with existing commercial assays.

Looking for Partners

Looking for a partner to validate testing, conduct pre-clinical and clinical testing, and commercialize the technology.


  • Increased specificity
  • Simplified and standardized
  • Determine type and stage of disease
  • Reduced cost


  • Detection of Lyme disease in: North America, animals, developing countries